A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers

Annals of Surgical Oncology

Volumn 15, Issue 8, 2008, Pages 2137-2145

  Stewart, John H ^a   Shen, Perry ^a   Russell, Greg ^a   Fenstermaker, Joyce ^a   McWilliams, Libby ^a   Coldrun, Faith M ^b   Levine, Keith E ^c   Jones, Bradley T ^b   Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Carcinomatosis; Intraperitoneal hyperthermic chemoperfusion; Oxaliplatin; Phase I trial; Surgery

Indexed keywords

OXALIPLATIN;

ABDOMINAL PAIN; ACIDOSIS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; APPENDIX CANCER; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CALCIUM BLOOD LEVEL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLAME PHOTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; ILEUS; INFECTION; INTRAPERITONEAL HYPERTHERMIC CHEMOPERFUSION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALABSORPTION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL COUNT; PARTIAL THROMBOPLASTIN TIME; PERITONEAL DISEASE; PERITONEAL FLUID; PERITONEAL SURFACE DISSEMINATION; PHASE 1 CLINICAL TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 48149084957     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9967-1     Document Type: Article

References (21)

1. SL Blair DZ Chu RE Schwarz 2001 Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer Ann Surg Oncol 8 632 7
2. DG Jayne S Fook C Loi 2002 Peritoneal carcinomatosis from colorectal cancer Br J Surg 89 1545 50
3. S Koga 1985 [Prophylactic and therapeutic continuous hyperthermic peritoneal perfusion for peritoneal metastases of gastric cancer] Gan No Rinsho 31 1103 5
4. EA Levine JH Stewart GB Russell 2007 Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures J Am Coll Surg 204 943 53
5. JH Stewart P Shen EA Levine 2005 Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions Ann Surg Oncol 12 765 77
6. JH Stewart P Shen GB Russell 2006 Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy Ann Surg Oncol 13 624 34
7. P Shen J Hawksworth J Lovato 2004 Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma Ann Surg Oncol 11 178 86
8. RL Dedrick MF Flessner 1997 Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure J Natl Cancer Inst 89 480 7
9. MF Flessner RL Dedrick JS Schultz 1984 A distributed model of peritoneal-plasma transport: theoretical considerations Am J Physiol 246 R597 607
10. O Rixe W Ortuzar M Alvarez 1996 Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem Pharmacol 52 1855 65
11. D Atallah V Marsaud C Radanyi 2004 Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines Int J Hyperthermia 20 405 19
12. M Urano CC Ling 2002 Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro Int J Hyperthermia 18 307 15
13. D Elias M Bonnay JM Puizillou 2002 Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution Ann Oncol 13 267 72
14. T Kuzuya M Yamauchi A Ito 1994 Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy J Pharm Pharmacol 46 685 9
15. F Levi G Metzger C Massari 2000 Oxaliplatin: pharmacokinetics and chronopharmacological aspects Clin Pharmacokinet 38 1 21
16. C Blacher J Neumann LA Jung 2005 Off-pump coronary artery bypass grafting does not reduce lymphocyte activation Int J Cardiol 101 473 9
17. G Bolla G Tuzzato 2003 Immunologic postoperative competence after laparoscopy versus laparotomy Surg Endosc 17 1247 50
18. GJ Hauser MM Chan WF Casey 1991 Immune dysfunction in children after corrective surgery for congenital heart disease Crit Care Med 19 874 81
19. P Shen EA Levine J Hall 2003 Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis Arch Surg 138 26 33
20. J Verweij J den Hartigh M Stuurman 1987 Relationship between clinical parameters and pharmacokinetics of mitomycin C J Cancer Res Clin Oncol 113 91 4
21. D Elias M Pocard D Goere 2007 HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin Cancer Treat Res 134 303 18